Would this help in stroke patients? Once again our stroke associations will fail by not following up on this with appropriate research. You'll have to wait 50 years because we have NO stroke strategy and no one that is even documenting anything resembling a strategy. We have NO stroke strategy by any of our stroke associations. They are all JUST WAITING FOR SOMEONE ELSE TO SOLVE THE PROBLEM!
http://dgnews.docguide.com/rotigotine-transdermal-patch-improves-swallowing-functions-patients-parkinson-s-disease?
The rotigotine transdermal patch improves swallowing functions in
patients with Parkinson’s disease (PD) who have difficulty swallowing,
according to a study presented here on September 27 at the 140th Annual
Meeting of the American Neurological Association (ANA).
“Abnormal swallowing, or dysphagia, is a potentially fatal symptom in
Parkinson’s disease, and several studies have reported that the
injection of apomorphine, a dopamine agonist, alleviated dysphagia in
some patients with PD,” said Makito Hirano, MD, Nara Medical University
School of Medicine, Nara, Japan. “Rotigotine is another dopamine agonist
with non-oral administration, and its non-invasiveness seems to render
this medicine even more suitable than apomorphine for patients with
dysphagia.”
To investigate the efficacy of the rotigotine transdermal patch for
dysphagia, the researchers conducted a retrospective, open-label study
in which they evaluated swallowing functions using videofluoroscopic
(VF) examination in 7 patients with PD and dysphagia (5 males and 2
females) at baseline and 1 to 2 weeks after treatment.
The evaluation was based on the scale established by the Japanese
Society of Dysphagia Rehabilitation, which can separately assess oral
and pharyngeal phases. The researchers also used Pharyngeal Transit
Duration (PTD), as well as the Dysphagia Outcome Severity Scale (DOSS)
to evaluate swallowing functions.
While the DOSS scores did not show significant changes, there were
statistically significant improvements in PTD and in the Japanese scale
scores during the oral and pharyngeal phases (P < .05, Wilcoxon
signed-rank test).
Dr. Hirano stressed that the study objectively showed -- for the
first time -- using videofluoroscopic examination, that rotigotine
improved swallowing in patients with dysphagia with PD.
“Although antiparkinsonian medications are thought to improve
swallowing during the oral phase, characterised mainly by voluntary
movements, our results showed that rotigotine additionally improved
swallowing during the pharyngeal phase, associated mainly with
sequential reflexes of striatal muscles,” he said.
[Presentation title: Improvement of Swallowing Functions by
Rotigotine Transdermal Patch in Patients With Parkinson’s Disease.
Abstract S427]
No comments:
Post a Comment